HIV Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Test Type (Antibody Tests, Viral Load Tests, CD4 Test, Others), By Mode, By End-use, By Region and Competition, 2020-2030F

Description

Global HIV Diagnostics market was valued at USD 4.53 billion in 2024 and is projected to reach USD 7.47 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.68%. Since the emergence of AIDS in the early 1980s, the HIV diagnostics landscape has evolved significantly. Advances in diagnostic technologies, increased public awareness, and broader access to testing have all played pivotal roles in the global response to the HIV/AIDS epidemic. Today, the HIV diagnostics sector represents a dynamic and rapidly advancing industry, offering renewed hope for improved disease management and, ultimately, eradication.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.53 Billion
Market Size 2030	USD 7.47 Billion
CAGR 2025-2030	8.68%
Fastest Growing Segment	Antibody Tests
Largest Market	North America

HIV (Human Immunodeficiency Virus) compromises the immune system by targeting CD4 cells, critical to defending against infections. Without timely treatment, HIV can progress to AIDS (Acquired Immunodeficiency Syndrome), increasing vulnerability to opportunistic infections and certain cancers. Despite ongoing efforts, the global HIV/AIDS epidemic remains a pressing public health concern, with millions affected worldwide. According to UNAIDS, approximately 38 million individuals were living with HIV as of 2019. While progress has been made in reducing infection rates and AIDS-related mortality, persistent challenges underscore the importance of accessible, accurate diagnostics in mitigating the virus's impact.

Market Drivers

Rising HIV Prevalence Fueling Demand for Diagnostics

The growing global prevalence of HIV/AIDS continues to be a major driver of the HIV diagnostics market. As per the World Health Organization (WHO), around 39.9 million people were living with HIV at the end of 2023, with Sub-Saharan Africa remaining the most affected region, accounting for over two-thirds of global cases. However, HIV continues to affect populations worldwide, reinforcing the universal demand for reliable diagnostic solutions.

Despite preventive measures and treatment advancements, the incidence of new HIV infections remains concerning. In 2023 alone, an estimated 1.3 million individuals acquired HIV. Contributing factors include limited access to preventive education, lack of contraceptive availability, and ongoing social stigma, which impedes testing and treatment efforts. The growing global population also means a rise in the absolute number of individuals living with HIV, thereby intensifying the need for early detection and clinical management.

Timely diagnosis is essential for initiating antiretroviral therapy (ART), which improves quality of life and reduces the risk of transmission. Early detection also helps prevent disease progression to AIDS, subsequently lowering mortality rates. In 2023, AIDS-related illnesses claimed approximately 630,000 lives worldwide. As such, the increasing burden of HIV has bolstered the demand for robust diagnostic tools, reinforcing their role in treatment planning, prevention, and public health management.

Market Challenges

Barriers to Accessibility and Awareness

Despite advancements, significant challenges persist, particularly in low- and middle-income countries where healthcare systems often lack the resources necessary for effective HIV diagnosis. In many rural and underserved areas, diagnostic services are limited due to poor infrastructure, inadequate transportation, and a shortage of trained medical personnel. These systemic gaps lead to late diagnoses and delayed treatment initiation.

Even in areas where diagnostic tools are available, factors such as inconsistent electricity supply, inadequate refrigeration for test kits, and substandard sanitary conditions compromise test accuracy. Moreover, social stigma, fear of discrimination, and misinformation continue to deter individuals from seeking testing. Misperceptions about personal risk and reluctance to discuss sexual health further hinder diagnosis efforts. In regions where comprehensive sex education is lacking, knowledge gaps contribute to the continued spread of HIV.

Cultural and language barriers, as well as insufficiently localized public health campaigns, further limit the effectiveness of outreach programs. Bridging these gaps requires a multifaceted strategy, including investment in healthcare infrastructure, community-based awareness initiatives, and integration of HIV testing into routine healthcare services. Closing the accessibility and awareness gap is crucial for improving early detection and reducing global HIV transmission rates.

Market Trends

Technological Innovation Driving Market Expansion

The HIV diagnostics market has been notably influenced by continuous advancements in testing technologies. One of the most transformative developments has been the rise of point-of-care testing (POCT) devices. These portable tools deliver rapid results-often within 30 minutes-enabling immediate clinical action and reducing transmission risks. POCT has been particularly valuable in resource-constrained environments lacking advanced laboratory infrastructure.

Nucleic acid testing (NAT) has further enhanced diagnostic accuracy by detecting the virus's genetic material directly, allowing for earlier identification and minimizing false-negative results. In parallel, next-generation sequencing (NGS) technologies have facilitated deeper understanding of HIV strain diversity, which is vital given the virus's high mutation rate. This knowledge supports the development of more targeted diagnostics and therapies.

Modern serological assays, such as chemiluminescence immunoassays and multiplex bead-based platforms, offer improved sensitivity and specificity. These tests can differentiate between HIV-1 and HIV-2 and are less susceptible to false positives.

Key Market Players

Thermo Fisher Scientific, Inc.
Alere Inc.
Abbott Laboratories inc.
Bristol-Myers Squibb Company
Janssen Global Services, LLC
Gilead Sciences, Inc.
Merck & Co. Inc.
VIIV Healthcare
Beckman Coulter, Inc.
Sysmex Europe SE
Zyomtronix, Inc.
Mylan N.V.
F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH

Report Scope:

In this report, the Global HIV Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV Diagnostics Market, By Product:

Consumables
Instruments
Software and Services

HIV Diagnostics Market, By Test Type:

Antibody Tests
Viral Load Tests
CD4 Test
Others

HIV Diagnostics Market, By Mode:

Self-Test
Lab-based

HIV Diagnostics Market, By End-use:

Diagnostic Laboratories
Hospitals & Clinics
Home Settings

HIV Diagnostics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV Diagnostics Market.

Available Customizations:

Global HIV Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global HIV Diagnostics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Consumables, Instruments, Software and Services)
- 5.2.2. By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others)
- 5.2.3. By Mode (Self-Test, Lab-based)
- 5.2.4. By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings)
- 5.2.5. By Company (2024)
- 5.2.6. By Region
5.3. Market Map

6. North America HIV Diagnostics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Test Type
- 6.2.3. By Mode
- 6.2.4. By End-use
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States HIV Diagnostics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Test Type
    - 6.3.1.2.3. By Mode
    - 6.3.1.2.4. By End-use
- 6.3.2. Mexico HIV Diagnostics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Test Type
    - 6.3.2.2.3. By Mode
    - 6.3.2.2.4. By End-use
- 6.3.3. Canada HIV Diagnostics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Test Type
    - 6.3.3.2.3. By Mode
    - 6.3.3.2.4. By End-use

7. Europe HIV Diagnostics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Test Type
- 7.2.3. By Mode
- 7.2.4. By End-use
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. France HIV Diagnostics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Test Type
    - 7.3.1.2.3. By Mode
    - 7.3.1.2.4. By End-use
- 7.3.2. Germany HIV Diagnostics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Test Type
    - 7.3.2.2.3. By Mode
    - 7.3.2.2.4. By End-use
- 7.3.3. United Kingdom HIV Diagnostics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Test Type
    - 7.3.3.2.3. By Mode
    - 7.3.3.2.4. By End-use
- 7.3.4. Italy HIV Diagnostics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Test Type
    - 7.3.4.2.3. By Mode
    - 7.3.4.2.4. By End-use
- 7.3.5. Spain HIV Diagnostics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Test Type
    - 7.3.5.2.3. By Mode
    - 7.3.5.2.4. By End-use

8. Asia-Pacific HIV Diagnostics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Test Type
- 8.2.3. By Mode
- 8.2.4. By End-use
- 8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China HIV Diagnostics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Test Type
    - 8.3.1.2.3. By Mode
    - 8.3.1.2.4. By End-use
- 8.3.2. India HIV Diagnostics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Test Type
    - 8.3.2.2.3. By Mode
    - 8.3.2.2.4. By End-use
- 8.3.3. South Korea HIV Diagnostics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Test Type
    - 8.3.3.2.3. By Mode
    - 8.3.3.2.4. By End-use
- 8.3.4. Japan HIV Diagnostics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Test Type
    - 8.3.4.2.3. By Mode
    - 8.3.4.2.4. By End-use
- 8.3.5. Australia HIV Diagnostics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Test Type
    - 8.3.5.2.3. By Mode
    - 8.3.5.2.4. By End-use

9. South America HIV Diagnostics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Test Type
- 9.2.3. By Mode
- 9.2.4. By End-use
- 9.2.5. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil HIV Diagnostics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Test Type
    - 9.3.1.2.3. By Mode
    - 9.3.1.2.4. By End-use
- 9.3.2. Argentina HIV Diagnostics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Test Type
    - 9.3.2.2.3. By Mode
    - 9.3.2.2.4. By End-use
- 9.3.3. Colombia HIV Diagnostics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Test Type
    - 9.3.3.2.3. By Mode
    - 9.3.3.2.4. By End-use

10. Middle East and Africa HIV Diagnostics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Test Type
- 10.2.3. By Mode
- 10.2.4. By End-use
- 10.2.5. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa HIV Diagnostics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Test Type
    - 10.3.1.2.3. By Mode
    - 10.3.1.2.4. By End-use
- 10.3.2. Saudi Arabia HIV Diagnostics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Test Type
    - 10.3.2.2.3. By Mode
    - 10.3.2.2.4. By End-use
- 10.3.3. UAE HIV Diagnostics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Test Type
    - 10.3.3.2.3. By Mode
    - 10.3.3.2.4. By End-use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porters Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Thermo Fisher Scientific, Inc.
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Alere Inc.
14.3. Abbott Laboratories inc.
14.4. Bristol-Myers Squibb Company
14.5. Janssen Global Services, LLC
14.6. Gilead Sciences, Inc.
14.7. Merck & Co. Inc.
14.8. VIIV Healthcare
14.9. Beckman Coulter, Inc.
14.10. Sysmex Europe SE
14.11. Zyomtronix, Inc.
14.12. Mylan N.V.
14.13. F. Hoffmann-La Roche Ltd.
14.14. Siemens Healthcare GmbH